Minoryx Therapeutics and Neuraxpharm's experimental therapy for genetic neurodegenerative disorder cerebral adrenoleukodystrophy (cALD) has shown that it can slow down the progression of the disease ...

The label CALD - which stands for culturally and linguistically diverse - has been widely used to describe certain communities, but is it still a useful term? For many Australians, cultural background ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cerebral adrenoleukodystrophy (CALD) is a rare progressive, genetic brain disease that primarily presents in young boys, causing loss of neurological function and ultimately leading to early death.

The term CALD is frequently being used to refer to “people of colour”, excluding Europeans from non-English speaking backgrounds. It can be a confusing label for those of mixed cultural heritage.

Bluebird bio could be just a few months away from approval of its gene therapy for rare disease cerebral adrenoleukodystrophy (CALD) in the EU, after the EMA started an accelerated review. If approved ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License ...

CALD is a rare neurodegenerative disease that can lead to progressive, irreversible loss of neurologic function, and death One-time treatment with SKYSONA has been shown to have a durable effect in ...